LONDON, July 31 (Reuters) - AstraZeneca (AZN.L) is still waiting to hear if the U.S. Food and Drug Administration will approve its new diabetes drug Onglyza but is confident on the product’s prospects, a spokesman said on Friday.
LONDON, July 31 (Reuters) - AstraZeneca (AZN.L) is still waiting to hear if the U.S. Food and Drug Administration will approve its new diabetes drug Onglyza but is confident on the product’s prospects, a spokesman said on Friday.
